Lilly's olomorasib receives FDA Breakthrough Therapy designation for advanced pancreatic cancer
The FDA has granted Breakthrough Therapy designation to olomorasib for advanced pancreatic cancer.
Regulatory Event
FDA Breakthrough Therapy designations for candidates showing substantial improvement over available therapies.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.